
Copyright:

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI link to article:

10.1212/NXG.0000000000000082

Date deposited:

26/07/2017

This work is licensed under a Creative Commons Attribution 4.0 International License
PATHOGENIC mtDNA MUTATIONS CAUSING MITOCHONDRIAL MYOPATHY: THE NEED FOR MUSCLE BIOPSY

OPEN

Pathogenic mitochondrial tRNA (mt-tRNA) gene mutations represent a prominent cause of primary mitochondrial DNA (mtDNA)-related disease despite accounting for only 5%-10% of the mitochondrial genome. Although some common mt-tRNA mutations, such as the m.3243A>G mutation, exist, the majority are rare and have been reported in only a small number of cases. The MT-TP gene, encoding mt-tRNA^{Pro}, is one of the less polymorphic mt-tRNA genes, and only 5 MT-TP mutations have been reported as a cause of mitochondrial muscle disease to date (table e-1 at Neurology.org/ng, P6–10). We report 5 patients with myopathic phenotypes, each harboring different pathogenic mutations in the MT-TP gene, highlighting the importance of MT-TP mutations as a cause of mitochondrial muscle disease and the requirement to study clinically relevant tissue.

Methods. All patients were referred to our specialist mitochondrial laboratory in Newcastle upon Tyne, UK. Diagnostic muscle biopsies were analyzed by standard histopathologic and biochemical techniques and a quadruple immunofluorescent assay to assess the expression of mitochondrial complex I and complex IV subunits. DNA was extracted using standard protocols; sequencing of the entire mitochondrial genome (GenBank Accession Number NC_012920.1) was undertaken using muscle DNA. Pyrosequencing was used to quantitatively assess mtDNA mutation heteroplasmic levels in available tissues and in laser-captured individual cytochrome c oxidase (COX)-positive and COX-deficient fibers.

Results. We identified 5 adult patients with mitochondrial disease due to mutations in the MT-TP gene; their clinical, histochemical, and genetic data are summarized in table e-1. Histopathologic analysis of muscle biopsies from all 5 patients revealed marked mitochondrial pathology in the form of a mosaic pattern of COX deficiency (figure 1A), which ranged from ~16% COX-deficient fibers in patient 3 up to >80% COX-deficient fibers from patients 2 and 5. COX-deficient ragged-red fibers were noted in all patients to varying degrees, although strongly succinate dehydrogenase–reactive blood vessels were not reported (figure 1A). Quantitative fluorescence-based immunohistochemistry confirmed decreased levels of both complex I (NDUFB8) and complex IV (COX-I) subunits, in accordance with an underlying disorder of mitochondrial translation (figure e-1).

Sequencing of the entire mitochondrial genome identified candidate MT-TP gene mutations at evolutionarily conserved positions in all 5 patients (figure 1, A and B; figure e-2). The m.15975T>C mutation and m.16002T>C mutation in patients 1 and 3, respectively, were previously reported, while those in patient 2 (m.15998A>T), patient 4 (m.16015T>C), and patient 5 (m.16021_16022del) were novel. In all cases, the highest mutation load was detectable in muscle, varying from 25% in patient 3 to >95% in patients 2 and 5 (table e-1). Screening of additional tissues was also performed; patients 1, 2, and 3 showed restricted expression of the MT-TP mutation to muscle, while patients 4 and 5 showed a hierarchical mutation segregation pattern (table e-1). Single muscle fiber segregation studies demonstrated statistically significant higher mutation levels in COX-deficient fibers compared with COX-positive fibers, thus confirming pathogenicity of each MT-TP mutation (figure 1C; table e-2).

Discussion. We report 5 adult patients with mitochondrial disease due to different mutations in the MT-TP gene with a predominantly myopathic phenotype. Ptosis (+/- progressive external ophthalmoplegia), proximal myopathy, and marked perceived fatigue appear to be salient features. In each case, the marked degree of COX deficiency and downregulation of both complex I and complex IV subunits in muscle was strongly suggestive of a defect in mitochondrial translation and entirely in keeping with an mt-tRNA mutation. To date, only 5 patients have been reported, each with different MT-TP mutations, and variable clinical features have been observed including ataxia, deafness, dilated cardiomyopathy, myoclonic epilepsy with ragged-red fibers–like disease, and retinitis pigmentosa; a myopathic phenotype is reported in all cases (table e-1).
Patients 1, 2, and 3 showed restricted expression of their *MT-TP* mutations to muscle, strongly indicative of a de novo mutational event, whereas patients 4 and 5 showed a hierarchical segregation pattern as observed in many pathogenic mtDNA mutations. Screening of maternal samples was undertaken for patients 2, 4, and 5, with maternal inheritance being confirmed in patient 4 only. Of note, only one of the previous studies demonstrated maternal inheritance of the *MT-TP* mutation, with 4 of the remaining studies also reporting apparent or likely de novo mutational events.

Single muscle fiber segregation studies remain the gold standard test to confidently establish pathogenicity of novel mtDNA variants. Although the m.15975T>C and m.16002T>C mutations have been reported previously, functional studies were not undertaken to confirm pathogenicity. Subsequent studies in muscle biopsies of all 5 patients confirm that mutation loads segregated with the mitochondrial histochemical defects in muscle (figure 1C; table e-2), powerfully illustrating an ongoing requirement to access pathologically relevant tissue—skeletal muscle—to support the investigation and diagnosis of patients with mitochondrial myopathy, even in the current era of high-throughput next-generation sequencing technologies.

Author contributions: S.A.H. analysis and interpretation of data, acquisition of data, statistical analysis, and writing of the manuscript. E.L.B. analysis and interpretation of data. A.I.P. analysis and interpretation of data. M.C.R. analysis and interpretation of data. S.A: analysis and interpretation of data. G.F: analysis and interpretation of data. J.P: acquisition of data and clinical investigations. M.R.R: acquisition of data and clinical investigations. O.O.M: acquisition of data and clinical investigations. N.B: analysis and interpretation of data. C.F.D: acquisition of data and clinical investigations. Y.S.N: acquisition of data and clinical investigations. R.H: acquisition of data and clinical investigations. D.M.T: critical revision of the manuscript for important intellectual content. G.S.G: study concept and design, critical revision of the manuscript for important intellectual content, study supervision and coordination. R.W.T: study concept and design, critical revision of the manuscript for important intellectual content, study supervision and coordination, obtaining funding.

Acknowledgment: The clinical and diagnostic mitochondrial services in both Newcastle upon Tyne and Oxford are funded by the UK NHS Highly Specialised Service for Rare Mitochondrial Disorders of Adults and Children.

Study funding: This study was funded by a Wellcome Trust Strategic Award (096912/Z/11/Z).

Disclosure: Dr. Hardy, Dr. Blakely, Dr. Purvis, Dr. Rocha, Ms. Ahmed, and Mr. Falkous report no disclosures. Dr. Poulton is supported by the Medical Research Council (UK) (MR/J010448/1), Wellcome Trust (094868/Z/10/Z), and the UK NHS Highly Specialised Service for Rare Mitochondrial Disorders of Adults and Children. Dr. Ruse serves on the editorial board of Cochrane Collaboration; and has received research support from the European Union, NIH, the Association Francatii centre Myologie (AFM), and Myositis UK. Dr. O’Mahony and Dr. Birmingham report no disclosures. Dr. Donegan has received travel funding/speaker honoraria from GRIFOLS; and has made small financial donations to the Walton Centre. Dr. Ng reports no disclosures. Dr. Horvath is supported by the Medical Research Council (UK) (G1000684) and the European Research Council (309548). Dr. Turnbull is supported by the Wellcome Trust Centre for Mitochondrial Research (096912/Z/11/Z), the MRC Centre for Translational Research in Neuromuscular Disease Mitochondrial Disease Patient Cohort (096912/Z/11/Z), the Lily Foundation and the UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to the Newcastle upon Tyne Foundation Hospitals NHS Trust. Dr. Gorman is supported by the UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to the Newcastle upon Tyne Foundation Hospitals NHS Trust; and is an employee of the University of Newcastle. Dr. Taylor is supported by the Wellcome Trust Centre for Mitochondrial Research (096912/Z/11/Z), the MRC Centre for Translational Research in Neuromuscular Disease Mitochondrial Disease Patient Cohort (UK) (G0800674), the Lily Foundation, and the UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to the Newcastle upon Tyne Foundation Hospitals NHS Trust. Go to Neurology.org/ng for full disclosure forms. The Article Processing Charge was paid by Newcastle University.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received March 22, 2016. Accepted in final form May 16, 2016.

Correspondence to Prof. Taylor: robert.taylor@ncl.ac.uk

Pathogenic mtDNA mutations causing mitochondrial myopathy: The need for muscle biopsy
Steven A. Hardy, Emma L. Blakely, Andrew I. Purvis, et al.
Neurol Genet 2016;2:
DOI 10.1212/NXG.0000000000000082

This information is current as of June 23, 2016